DAMORA THERAPEUTICS INC (DMRA)
Health Care · Biotechnology · NASDAQ
Damora Therapeutics is a clinical-stage biopharma company developing next-generation antibody therapies to treat myeloproliferative neoplasms by targeting mutant calreticulin.
What DAMORA THERAPEUTICS INC does
Damora Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for hematologic disorders, specifically myeloproliferative neoplasms (MPNs). The company utilizes a proprietary portfolio of product candidates that target mutant forms of the calcium-binding protein calreticulin (mutCALR) to address the underlying drivers of these bone marrow disorders.
Themes: oncology / hematology, myeloproliferative neoplasms (MPNs), antibody therapeutics, mutCALR-targeting therapies
Fundamentals
- Price$20.67 as of 2026-10-20 close
- Market cap$1.3B as of 2026-08-07 (share count; price 2026-10-20)
- 1-year return+119.2% 2025-10-20 close $9.43 → 2026-10-20 close $20.67
- P/E2.68 as of 2026-10-20
- ROE-87.3% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.40 as of 2026-09-03
- Last reported earnings2026-03-10 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How DMRA compares in its sector
- price-to-earnings ratiobottom 10% 181 covered Health Care peers, as of 2026-10-20
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$35M | -$31M | -$0.39 | -$22M† |
| Q1 FY2026 2026-03-31 | -$31M | -$28M | -$0.62 | -$21M |
| Q4 FY2025 2025-12-31 | -$202M† | -$201M† | $10.86† | $566000† |
| Q3 FY2025 2025-09-30 | -$3M | -$3M | -$2.36 | -$3M† |
| Q2 FY2025 2025-06-30 | -$3M | -$3M | -$2.60 | -$2M† |
| Q1 FY2025 2025-03-31 | -$3M | -$3M | -$1.92 | -$2M |
| Q4 FY2024 2024-12-31 | -$7M† | -$7M† | -$5.23† | -$5M† |
| Q3 FY2024 2024-09-30 | -$4M | -$4M | -$3.39 | -$4M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$541M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How DAMORA THERAPEUTICS INC looks technically
DAMORA THERAPEUTICS INC (DMRA) is trading 19.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 4 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day low about 5 trading days ago. It is 46.1% below its highest point of the past year. Trading volume is unusually light — only about 34% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 19.4% below its 200-day average, the long-term trend line — a long-term downtrend | -19.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $25.05 | $25.05 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $25.63 | $25.63 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 21.86. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 4 trading days ago — a "death cross", a bearish long-term signal | 4 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 32.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 45.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($17.49 to $21.86) — its "stochastic" reading is 73 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 72.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $38.33 | $38.33 |
|---|---|---|
| From the 52-week high | it is 46.1% below its 52-week high (its highest price of the past year) | -46.1% |
| Above the 52-week low | it is 317.6% above its 52-week low (its lowest price of the past year) | +317.6% |
| Below the 52-week high | it is 46.1% below its highest point of the past year | 46.1% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $449.75 (set on 2020-11-23) | $449.75 |
| Given back of the 52-week move | over the past year its closes ranged ($4.95 to $34.14), and it has given back around half of its rise from last year’s low — 46% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.17 to $16.10. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 46.1% |
| From the all-time high | it is 95.4% below its all-time high | -95.4% |
| Nearest price level | it is trading 6.1% above a support level at $19.41 — a price it turned at twice since 2026-01-08, most recently on 2026-09-24. Since 2024-10-21 it has 3 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -6.1% |
| All-time low | its lowest closing price on record is $2.01 (set on 2025-04-09) | $2.01 |
| Above the all-time low | it is 928.4% above its all-time low | +928.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.53 between its high and its low — about 7.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.53 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.31 and $21.79 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.31 – $20.05 – $21.79 |
| Typical daily range (% of price) | its price moves about 7.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.4% |
| Stretch from the 200-day average | it is trading 3.2 daily ranges below its 200-day average price (19.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 34% of its 30-day average | 0.34× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.2% |
|---|---|---|
| Gap filled | a 3.6% gap down opened on 2026-10-01 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it took 6 sessions to close | 7 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +12.09% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.5 percentage points (the stock lost 8.5% while the market gained 1.0%) | -9.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 41.0 percentage points (the stock lost 37.3% while the market gained 3.6%) | -41.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 30.3 percentage points (the stock lost 21.8% while the market gained 8.5%) | -30.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 104.6 percentage points (the stock gained 119.2% while the market gained 14.6%) | +104.6% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 28% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.8% of the share price. | -28.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $25.27 — a volume-weighted average of daily closes over 200 sessions, not a true tick-by-tick VWAP. | -18.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $23.92 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -13.6% |
Price levels it has turned at before
DMRA last closed at $20.67 on 2026-10-20. Since 2024-10-21 it has turned at 3 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.41 | Support | 6.1% below the last close | turned there twice · 2026-01-08 to 2026-09-24 |
| $21.93 | Resistance | 6.1% above the last close | turned there twice · 2026-05-12 to 2026-10-09 |
| $23.06 | Resistance | 11.6% above the last close | turned there twice · 2026-04-07 to 2026-04-29 |
| $26.43 | Resistance | 27.9% above the last close | turned there three times · 2026-05-27 to 2026-08-31 |
| $4.99 | Support | 75.9% below the last close | turned there three times · 2025-02-18 to 2025-11-07 |
| $3.09 | Support | 85.0% below the last close | turned there three times · 2025-06-18 to 2025-07-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $21.86.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $10.48 and $17.51 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-10-16.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.10 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$46.89 range $40.00 – $60.00; median $45.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DMRA
- Consensus EPS estimate-$0.435 next reporting period, as of 2026-10-15
- Estimate change, 30 days$0.00 from -$0.435, on 2026-09-10, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial success and regulatory approval uncertainty for pipeline assets.","Reliance on third-party research collaboration with Paragon Therapeutics.","Early-stage development risk with limited operating history as currently configured."]
What changed in the latest 10-Q
AI-assisted comparison of DMRA's 10-Q filed 2026-08-10 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-10) states the first product candidate 'recently received approval to begin a Phase 1/1b clinical trial'.
- Newer filing (2026-08-10) adds a sentence stating 'Both DMR-001 and DMR-002 were designed to have an extended half-life supporting convenient once-monthly subcutaneous administration.'
- Newer filing (2026-08-10) adds the sentence 'We recently initi' at the end of the provided text.
- Removed:
- Older filing (2026-05-12) stated 'In our previously announced Asset Acquisition, we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms ("MPNs"), a group of related, chronic disorders of the bone marrow.'
- Older filing (2026-05-12) included the sentence 'We intend to make our first regulatory submissions enabling the start of clinical development for DMR-001 and DMR-002 in mid-2026 and the second half of 2026, respectively, and for DMR-003 in 2027.'
- Reworded:
- Older filing (2026-05-12): 'Combined with proprietary antibody design features enabling high potency across CALR mutation types and extended half-life supporting convenient subcutaneous administration, we believe each asset profile has best-in-class potential.' Newer filing (2026-08-10): 'Combined with proprietary antibody design features enabling high potency across CALR mutation types, we believe each asset profile has best-in-class potential.' (removed reference to extended half-life in this sentence, moved to a separate sentence)
- Older filing (2026-05-12): 'We believe that the potential combination of increased clinical activity and improved pharmacokinetics of DMR-001 positions it as a potential best-in-class therapy for ET and MF.' Newer filing (2026-08-10): 'We believe that DMR-001's potential to combine increased clinical activity against all mutCALR subtypes and improved pharmacokinetics enabling optimized subcutaneous administration position it as a potential best-in-class therapy for patients with ET and MF.'
- Older filing (2026-05-12): 'Our ultimate goal is to develop a portfolio...' Newer filing (2026-08-10): 'Our goal is to develop a portfolio...' (word 'ultimate' removed)
- Older filing (2026-05-12): 'In our previously announced Asset Acquisition, we bolstered our pipeline with the addition of three product candidates...' Newer filing (2026-08-10): 'We currently have three product candidates designed to treat myeloproliferative neoplasms ("MPNs"), a group of related, chronic disorders of the bone marrow, the first of which recently received approval to begin a Phase 1/1b clinical trial.'
- Notes:
- Newer filing text appears truncated at 'We recently initi' and may be incomplete.
- Comparison limited to the provided excerpt of the MD&A section; additional changes outside this excerpt are not assessed.
Risk Factors
- Added:
- Newer filing (2026-08-10) adds a new summary bullet under 'Risks Related to the Ownership of Our Ordinary Shares'? No—actually the bullet about market price volatility appears in both; the heading change is noted separately. Newer filing adds the heading 'Risks Related to the Ownership of Our Ordinary Shares' before the market price bullet, whereas older filing placed this heading after the General Risk Factors section.
- Removed:
- Older filing (2026-05-12) includes the heading 'Risks Related to the Ownership of Our Common Stock'; in the newer filing (2026-08-10) this is replaced by 'Risks Related to the Ownership of Our Ordinary Shares' and moved earlier in the summary.
- Reworded:
- In the Risk Factor Summary, the bullet 'There is no guarantee that our acquisition of Pre-Acquisition Damora in November 2025 will increase stockholder value' in the older filing (2026-05-12) is changed to '...will increase shareholder value' in the newer filing (2026-08-10).
- In the detailed risk factor text, the older filing (2026-05-12) states 'will not impair stockholder value or otherwise adversely affect our business' and 'impair the value of the Asset Acquisition to our stoc' (truncated); the newer filing (2026-08-10) states 'will not impair shareholder value or otherwise adversely affect our business' and 'impair the value of the Asset Acquisition to ou' (truncated).
- The heading 'Risks Related to the Ownership of Our Common Stock' (older filing, filed 2026-05-12) is changed to 'Risks Related to the Ownership of Our Ordinary Shares' in the newer filing (filed 2026-08-10).
- The bullet 'The market price of our Common Stock has been and is expected to continue to be volatile.' in the older filing (2026-05-12) is changed to 'The market price of our Ordinary Shares has been and is expected to continue to be volatile.' in the newer filing (2026-08-10).
- Notes:
- The detailed risk factor text in both filings is truncated at the end of the section, so comparison beyond the truncation point is not possible.
- The newer filing's summary inserts 'Risks Related to the Ownership of Our Ordinary Shares' before 'General Risk Factors', while the older filing places that ownership-related heading after 'General Risk Factors'; this reordering is captured but not characterized as material.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-161 buy ($252875) · 0 sells — 1 buying insider
- Last 90 days · read to 2026-10-161 buy ($252875) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-161 buy ($252875) · 1 sell ($7345) — 1 buying, 1 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-25. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DMRA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding DMRA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 11,762,922
- Reported value $304,659,680
reported quarterly holdings change (2025-12-31 → 2026-03-31): 2 new, 2 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about DMRA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
DMRA had 4,733,297 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
DMRA had 7.67% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.8 days to cover at the same settlement.
- Reported short interest (shares) 4,733,297
- Short interest (% of shares outstanding) 7.67%
- Prior settlement (shares) 4,732,463
- Reported change 0.02%
- Days to cover (reported) 4.8
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
DMRA ranks in…
Frequently asked questions
What does DAMORA THERAPEUTICS INC (DMRA) do?
Damora Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for hematologic disorders, specifically myeloproliferative neoplasms (MPNs). The company utilizes a proprietary portfolio of product candidates that target mutant forms of the calcium-binding protein calreticulin (mutCALR) to address the underlying drivers of these bone marrow disorders.
What sector is DAMORA THERAPEUTICS INC (DMRA) in?
DAMORA THERAPEUTICS INC (DMRA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is DAMORA THERAPEUTICS INC (DMRA) overbought or oversold right now?
DAMORA THERAPEUTICS INC (DMRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DMRA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.